Live Webinar | October 29 at 2pm ET | Explore the benefits of integrating DNA sequencing and AI for AAV genome integrity characterization in accelerated gene therapy.
AAV genomic integrity is based on defining the molecular DNA composition of recombinant AAV vector preparations, specifically, the presence of full-length, ITR-to-ITR genomes, and the relative amount of undesirable molecular sub-species encapsidated within AAV particles. Variation in the profile of the intact AAV vector genome leads to product heterogeneity and contaminants that might impact safe and effective biological outcomes.
This webinar explores the role of long-read sequencing in assessing genome integrity. Characterizing the molecular profile may provide insights that could inform more effective vector design early in the research phase, shorten development timelines, and reduce cost-of-goods. Highlights include:
- Benefits compared to orthogonal methods.
- How genome integrity profiling can inform AI models to evaluate vector conformations computationally for predictive outcomes.
- How to incorporate long-read sequencing into process development workflows.
Offered Free by: BioPharma Dive’s studioID and Catalent
See All Resources from: BioPharma Dive’s studioID and Catalent
